Name | 4-(8-methyl-9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline |
---|---|
Synonyms |
Benzenamine, 4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-, hydrochloride (1:1)
1-(p-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride 4-(8-Methyl-9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline hydrochloride (1:1) |
Description | GYKI 52466 is a potent antagonist of kainate- and AMPA-activated currents (IC50 values, 7.5 and 11 μM, respectively), GYKI 52466 can be used for the research of neurological disorders, such as Parkinson's disease[1]. |
---|---|
Related Catalog | |
In Vivo | GYKI 52466 (1.76-13.2 mg/kg; male and female DBA/2 mice; intraperitoneal injection) treatment provides potent anticonvulsant protection against sound-induced seizures in DBA/2 mice. The ED50 value at 15 min for the protection against sound-induced seizures in DBA/2 mice is 13.7 (11.5-16.5) μmol/kg (GYKI 52466, i.p.), The ED50 value for the protection against AMPA-induced seizures by GYKI 52466 (15 min i.p.) is 18.5 (11.5–29.5) μmol/kg[2]. Animal Model: Animal model: male and female DBA/2 mice tested for sound-induced seizure responses[2] Dosage: 1.76-13.2 mg/kg (6-45 μmol/kg) Administration: Intraperitoneal injection; 1.76-13.2 mg/kg (6-45 μmol/kg); once; 5 min, 15 min, 30 min Result: Observed Maximal anticonvulsant protection after the i.p. administration (5–15 min ) of GYKI 52466 in DBA/2 mice. |
References |
Boiling Point | 472.8ºC at 760 mmHg |
---|---|
Molecular Formula | C17H16ClN3O2 |
Molecular Weight | 329.781 |
Flash Point | 239.7ºC |
Exact Mass | 329.093109 |
PSA | 69.20000 |
LogP | 3.02130 |
Vapour Pressure | 4.15E-09mmHg at 25°C |